The findings suggest that use of the pacing technique during CRT should be reserved for expert operators, at least for now.

Conduction system pacing was found to be inferior to biventricular pacing for key outcomes in HFrEF with left bundle-branch ...

Cardiac resynchronization therapy is a key treatment for patients with HFrEF and electrical dyssynchrony, such as LBBB. While ...

Medtronic and Biotronik both took steps forward this week with their pacemaker hardware designed to target newly emerging ...

Medtronic announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

Medtronic snagged FDA approval for an expanded indication for its OmniaSecure defibrillation lead. Check out why this tiny ...

Late-breaking data from Abbott (ABT)'s groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has ...

Conduction system pacing (CSP) produced the same degree of cardiac resynchronization, ventricular reverse modeling, and similar clinical outcomes as did biventricular pacing (BiVP) in patients with ...

Abbott (ABT)'s investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) ...

Pacing as a device therapy for heart failure (HF) is headed for what is probably its next big advance. After decades of biventricular (BiV) pacemaker success in resynchronizing the ventricles and ...